{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:59:43Z","timestamp":1790812783187,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10147-019-01460-8","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T16:33:55Z","timestamp":1557160435000},"page":"1204-1213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A)"],"prefix":"10.1007","volume":"24","author":[{"given":"Shun","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Shimose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanae","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Akagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kakeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"key":"1460_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-017-1101-6","volume":"23","author":"T Watanabe","year":"2018","unstructured":"Watanabe T, Muro K, Ajioka Y et al (2018) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23:1\u201334. \n                    https:\/\/doi.org\/10.1007\/s10147-017-1101-6","journal-title":"Int J Clin Oncol"},{"key":"1460_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1136\/bmj.306.6880.752","volume":"306","author":"W Scheithauer","year":"1993","unstructured":"Scheithauer W, Rosen H, Kornek GV et al (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306:752\u2013755. \n                    https:\/\/doi.org\/10.1177\/2325967117745788","journal-title":"BMJ"},{"key":"1460_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/bmj.321.7260.531","volume":"321","author":"PC Simmonds","year":"2000","unstructured":"Simmonds PC (2000) Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 321:531\u2013535","journal-title":"BMJ"},{"key":"1460_CR4","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","volume":"352","author":"D Cunningham","year":"1998","unstructured":"Cunningham D, Pyrhonen S, James RD et al (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413\u20131418. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(98)02309-5","journal-title":"Lancet"},{"key":"1460_CR5","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013\u20132019. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.14.9930","journal-title":"J Clin Oncol"},{"key":"1460_CR6","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1200\/JCO.2008.19.9273","volume":"27","author":"R Adam","year":"2009","unstructured":"Adam R, Wicherts DA, de Haas RJ et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829\u20131835. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.19.9273","journal-title":"J Clin Oncol"},{"key":"1460_CR7","doi-asserted-by":"publisher","first-page":"990S","DOI":"10.1093\/jn\/127.5.990S","volume":"127","author":"IH Rosenberg","year":"1997","unstructured":"Rosenberg IH (1997) Sarcopenia: origins and clinical relevance. J Nutr 127:990S\u2013S991. \n                    https:\/\/doi.org\/10.1093\/jn\/127.5.990S","journal-title":"J Nutr"},{"key":"1460_CR8","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1093\/ajcn\/50.5.1231","volume":"50","author":"IH Rosenberg","year":"1989","unstructured":"Rosenberg IH (1989) Epidemiologic and methodologic problems in determining nutritional status of older persons. Proceedings of a conference. Albuquerque, New Mexico, October 19\u201321, 1988. Am J Clin Nutr 50:1121\u20131235","journal-title":"Am J Clin Nutr"},{"key":"1460_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ageing\/afq034","volume":"39","author":"AJ Cruz-Jentoft","year":"2010","unstructured":"Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 39:412\u2013423. \n                    https:\/\/doi.org\/10.1093\/ageing\/afq034","journal-title":"Age Ageing"},{"key":"1460_CR10","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1007\/s00268-018-4554-5","volume":"42","author":"H Saeki","year":"2018","unstructured":"Saeki H, Nakashima Y, Kudou K et al (2018) Neoadjuvant chemoradiotherapy for patients with cT3\/nearly T4 esophageal cancer: is sarcopenia correlated with postoperative complications and prognosis? World J Surg 42:2894\u20132901. \n                    https:\/\/doi.org\/10.1007\/s00268-018-4554-5","journal-title":"World J Surg"},{"key":"1460_CR11","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1245\/s10434-017-6328-y","volume":"25","author":"S Takamori","year":"2018","unstructured":"Takamori S, Toyokawa G, Okamoto T et al (2018) Clinical impact and risk factors for skeletal muscle loss after complete resection of early non-small cell lung cancer. Ann Surg Oncol 25:1229\u20131236. \n                    https:\/\/doi.org\/10.1245\/s10434-017-6328-y","journal-title":"Ann Surg Oncol"},{"key":"1460_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00595-017-1564-0","volume":"48","author":"R Nakanishi","year":"2018","unstructured":"Nakanishi R, Oki E, Sasaki S et al (2018) Sarcopenia is an independent predictor of complications after colorectal cancer surgery. Surg Today 48:151\u2013157. \n                    https:\/\/doi.org\/10.1007\/s00595-017-1564-0","journal-title":"Surg Today"},{"key":"1460_CR13","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1245\/s10434-017-5811-9","volume":"24","author":"K Kudou","year":"2017","unstructured":"Kudou K, Saeki H, Nakashima Y et al (2017) Prognostic significance of sarcopenia in patients with esophagogastric junction cancer or upper gastric cancer. Ann Surg Oncol 24:1804\u20131810. \n                    https:\/\/doi.org\/10.1245\/s10434-017-5811-9","journal-title":"Ann Surg Oncol"},{"key":"1460_CR14","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/hepr.12674","volume":"46","author":"N Harimoto","year":"2016","unstructured":"Harimoto N, Yoshizumi T, Shimokawa M et al (2016) Sarcopenia is a poor prognostic factor following hepatic resection in patients aged 70 years and older with hepatocellular carcinoma. Hepatol Res 46:1247\u20131255. \n                    https:\/\/doi.org\/10.1111\/hepr.12674","journal-title":"Hepatol Res"},{"key":"1460_CR15","doi-asserted-by":"publisher","first-page":"e0129742","DOI":"10.1371\/journal.pone.0129742","volume":"10","author":"Y Miyamoto","year":"2015","unstructured":"Miyamoto Y, Baba Y, Sakamoto Y et al (2015) Negative impact of skeletal muscle loss after systemic chemotherapy in patients with unresectable colorectal cancer. PLoS ONE 10:e0129742. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0129742","journal-title":"PLoS ONE"},{"key":"1460_CR16","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1200\/JCO.2015.63.6043","volume":"34","author":"S Blauwhoff-Buskermolen","year":"2016","unstructured":"Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MA et al (2016) Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol 34:1339\u20131344. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.63.6043","journal-title":"J Clin Oncol"},{"key":"1460_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000346690","volume":"84","author":"E Oki","year":"2013","unstructured":"Oki E, Emi Y, Akagi Y et al (2013) Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701). Oncology 84:233\u2013239. \n                    https:\/\/doi.org\/10.1159\/000346690","journal-title":"Oncology"},{"key":"1460_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s10147-015-0850-3","volume":"21","author":"K Miwa","year":"2016","unstructured":"Miwa K, Oki E, Emi Y et al (2016) Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). Int J Clin Oncol 21:110\u2013117. \n                    https:\/\/doi.org\/10.1007\/s10147-015-0850-3","journal-title":"Int J Clin Oncol"},{"key":"1460_CR19","first-page":"6655","volume":"34","author":"T Beppu","year":"2014","unstructured":"Beppu T, Emi Y, Tokunaga S et al (2014) Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study). Anticancer Res 34:6655\u20136662","journal-title":"Anticancer Res"},{"key":"1460_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10147-015-0895-3","volume":"21","author":"Y Ogata","year":"2016","unstructured":"Ogata Y, Shimokawa M, Tanaka T et al (2016) A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902). Int J Clin Oncol 21:335\u2013343. \n                    https:\/\/doi.org\/10.1007\/s10147-015-0895-3","journal-title":"Int J Clin Oncol"},{"issue":"Suppl 3","key":"1460_CR21","doi-asserted-by":"publisher","first-page":"S1067","DOI":"10.1245\/s10434-015-4771-1","volume":"22","author":"E Oki","year":"2015","unstructured":"Oki E, Emi Y, Miyamoto Y et al (2015) Phase II trial of S-1 and oxaliplatin plus cetuximab for colorectal cancer patients with initially unresectable or not optimally resectable liver metastases (KSCC1002). Ann Surg Oncol 22(Suppl 3):S1067\u2013S1074. \n                    https:\/\/doi.org\/10.1245\/s10434-015-4771-1","journal-title":"Ann Surg Oncol"},{"key":"1460_CR22","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10147-017-1140-z","volume":"22","author":"K Ando","year":"2017","unstructured":"Ando K, Emi Y, Suenaga T et al (2017) A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101). Int J Clin Oncol 22:913\u2013920. \n                    https:\/\/doi.org\/10.1007\/s10147-017-1140-z","journal-title":"Int J Clin Oncol"},{"key":"1460_CR23","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1152\/japplphysiol.00744.2004","volume":"97","author":"W Shen","year":"1985","unstructured":"Shen W, Punyanitya M, Wang Z et al (1985) (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 97:2333\u20132338. \n                    https:\/\/doi.org\/10.1152\/japplphysiol.00744.2004","journal-title":"J Appl Physiol"},{"key":"1460_CR24","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1139\/H08-075","volume":"33","author":"M Mourtzakis","year":"2008","unstructured":"Mourtzakis M, Prado CM, Lieffers JR et al (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33:997\u20131006. \n                    https:\/\/doi.org\/10.1139\/H08-075","journal-title":"Appl Physiol Nutr Metab"},{"key":"1460_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1152\/jappl.1998.85.1.115","volume":"85","author":"N Mitsiopoulos","year":"1998","unstructured":"Mitsiopoulos N, Baumgartner RN, Heymsfield SB et al (1998) Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol (1985) 85:115\u2013122. \n                    https:\/\/doi.org\/10.1152\/jappl.1998.85.1.115","journal-title":"J Appl Physiol (1985)"},{"key":"1460_CR26","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0140-6736(97)11518-5","volume":"351","author":"KD Miller","year":"1998","unstructured":"Miller KD, Jones E, Yanovski JA et al (1998) Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351:871\u2013875. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(97)11518-5","journal-title":"Lancet"},{"key":"1460_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","volume":"9","author":"CM Prado","year":"2008","unstructured":"Prado CM, Lieffers JR, McCargar LJ et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629\u2013635. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(08)70153-0","journal-title":"Lancet Oncol"},{"key":"1460_CR28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.diabres.2007.10.016","volume":"79","author":"R Oka","year":"2008","unstructured":"Oka R, Kobayashi J, Yagi K et al (2008) Reassessment of the cutoff values of waist circumference and visceral fat area for identifying Japanese subjects at risk for the metabolic syndrome. Diabetes Res Clin Pract 79:474\u2013481. \n                    https:\/\/doi.org\/10.1016\/j.diabres.2007.10.016","journal-title":"Diabetes Res Clin Pract"},{"key":"1460_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489\u2013495. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7","journal-title":"Lancet Oncol"},{"key":"1460_CR30","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.clnu.2007.03.011","volume":"26","author":"RJ Skipworth","year":"2007","unstructured":"Skipworth RJ, Stewart GD, Dejong CH et al (2007) Pathophysiology of cancer cachexia: much more than host\u2013tumour interaction? Clin Nutr 26:667\u2013676. \n                    https:\/\/doi.org\/10.1016\/j.clnu.2007.03.011","journal-title":"Clin Nutr"},{"key":"1460_CR31","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/jcsm.12275","volume":"9","author":"T Zhou","year":"2018","unstructured":"Zhou T, Wang B, Liu H et al (2018) Development and validation of a clinically applicable score to classify cachexia stages in advanced cancer patients. J Cachexia Sarcopenia Muscle 9:306\u2013314. \n                    https:\/\/doi.org\/10.1002\/jcsm.12275","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1460_CR32","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/01635581.2014.894103","volume":"66","author":"M Barret","year":"2014","unstructured":"Barret M, Antoun S, Dalban C et al (2014) Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer 66:583\u2013589. \n                    https:\/\/doi.org\/10.1080\/01635581.2014.894103","journal-title":"Nutr Cancer"},{"key":"1460_CR33","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00520-014-2418-6","volume":"23","author":"HW Jung","year":"2015","unstructured":"Jung HW, Kim JW, Kim JY et al (2015) Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer 23:687\u2013694. \n                    https:\/\/doi.org\/10.1007\/s00520-014-2418-6","journal-title":"Support Care Cancer"},{"key":"1460_CR34","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860\u2013867. \n                    https:\/\/doi.org\/10.1038\/nature01322","journal-title":"Nature"},{"key":"1460_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1385\/IR:23:1:41","volume":"23","author":"BE Barton","year":"2001","unstructured":"Barton BE (2001) IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation. Immunol Res 23:41\u201358. \n                    https:\/\/doi.org\/10.1385\/IR:23:1:41","journal-title":"Immunol Res"},{"key":"1460_CR36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/(SICI)1098-1128(199905)19:3<223::AID-MED3>3.0.CO;2-N","volume":"19","author":"JM Argiles","year":"1999","unstructured":"Argiles JM, Lopez-Soriano FJ (1999) The role of cytokines in cancer cachexia. Med Res Rev 19:223\u2013248","journal-title":"Med Res Rev"},{"key":"1460_CR37","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1186\/s12885-017-3562-4","volume":"17","author":"T Naito","year":"2017","unstructured":"Naito T, Okayama T, Aoyama T et al (2017) Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer. BMC Cancer 17:571. \n                    https:\/\/doi.org\/10.1186\/s12885-017-3562-4","journal-title":"BMC Cancer"},{"key":"1460_CR38","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/nrc.2017.78","volume":"17","author":"GJ Koelwyn","year":"2017","unstructured":"Koelwyn GJ, Quail DF, Zhang X et al (2017) Exercise-dependent regulation of the tumour microenvironment. Nat Rev Cancer 17:620\u2013632. \n                    https:\/\/doi.org\/10.1038\/nrc.2017.78","journal-title":"Nat Rev Cancer"},{"key":"1460_CR39","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.1158\/1078-0432.CCR-16-0067","volume":"22","author":"CM Friedenreich","year":"2016","unstructured":"Friedenreich CM, Neilson HK, Farris MS (2016) Physical activity and cancer outcomes: a precision medicine approach. Clin Cancer Res 22:4766\u20134775. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0067","journal-title":"Clin Cancer Res"},{"key":"1460_CR40","doi-asserted-by":"publisher","first-page":"E197","DOI":"10.1002\/ijc.29142","volume":"136","author":"NP Gannon","year":"2015","unstructured":"Gannon NP, Vaughan RA, Garcia-Smith R et al (2015) Effects of the exercise-inducible myokine irisin on malignant and non-malignant breast epithelial cell behavior in vitro. Int J Cancer 136:E197\u2013E202. \n                    https:\/\/doi.org\/10.1002\/ijc.29142","journal-title":"Int J Cancer"},{"key":"1460_CR41","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.bbrc.2016.12.084","volume":"485","author":"L Shao","year":"2017","unstructured":"Shao L, Li H, Chen J et al (2017) Irisin suppresses the migration, proliferation, and invasion of lung cancer cells via inhibition of epithelial-to-mesenchymal transition. Biochem Biophys Res Commun 485:598\u2013605. \n                    https:\/\/doi.org\/10.1016\/j.bbrc.2016.12.084","journal-title":"Biochem Biophys Res Commun"},{"key":"1460_CR42","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.bbrc.2017.08.148","volume":"493","author":"G Shi","year":"2017","unstructured":"Shi G, Tang N, Qiu J et al (2017) Irisin stimulates cell proliferation and invasion by targeting the PI3K\/AKT pathway in human hepatocellular carcinoma. Biochem Biophys Res Commun 493:585\u2013591. \n                    https:\/\/doi.org\/10.1016\/j.bbrc.2017.08.148","journal-title":"Biochem Biophys Res Commun"},{"key":"1460_CR43","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1136\/gutjnl-2011-300776","volume":"62","author":"W Aoi","year":"2013","unstructured":"Aoi W, Naito Y, Takagi T et al (2013) A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise. Gut 62:882\u2013889. \n                    https:\/\/doi.org\/10.1136\/gutjnl-2011-300776","journal-title":"Gut"},{"key":"1460_CR44","doi-asserted-by":"publisher","first-page":"156.e9","DOI":"10.1016\/j.urolonc.2017.09.016","volume":"36","author":"H Fukushima","year":"2018","unstructured":"Fukushima H, Kataoka M, Nakanishi Y et al (2018) Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Urol Oncol 36:156.e9\u2013156.e16. \n                    https:\/\/doi.org\/10.1016\/j.urolonc.2017.09.016","journal-title":"Urol Oncol"},{"key":"1460_CR45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","volume":"57","author":"SS Shachar","year":"2016","unstructured":"Shachar SS, Williams GR, Muss HB et al (2016) Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer 57:58\u201367. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2015.12.030","journal-title":"Eur J Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01460-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-019-01460-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01460-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T23:33:30Z","timestamp":1588635210000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-019-01460-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,6]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1460"],"URL":"https:\/\/doi.org\/10.1007\/s10147-019-01460-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,6]]},"assertion":[{"value":"10 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"We declare that we have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}